Eric F Morand, Vera Golder, Rangi Kandane-Rathnayake
The goal of care in any medical condition is to optimise a person's current health status, with a view to positively impacting on their long-term outcomes. Since 2014 the concept of treat-to-target (T2T) in systemic lupus erythematosus (SLE) has been in development, enabled by a paradigm shift to focus on attainable treatment targets allowing for the development, validation, and adoption of a T2T approach. In this review, the history of this paradigm change will be reviewed, along with evidence from clinical trials that show increasing likelihood of achievement of these goals with more effective treatments and the associated benefit of reduced corticosteroid burden.